In a report released yesterday, Sean Lavin from BTIG maintained a Buy rating on Boston Scientific Corp (BSX), with a price target of $46. The company’s shares closed yesterday at $42.87, close to its 52-week high of $43.66.
According to TipRanks.com, Lavin is a 4-star analyst with an average return of 5.6% and a 57.8% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings Inc, Helius Medical Technologies, and Tactile Systems Technology.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Boston Scientific Corp with a $47.04 average price target, representing a 9.7% upside. In a report issued on July 10, Citigroup also maintained a Buy rating on the stock with a $50 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $43.66 and a one-year low of $31.56. Currently, Boston Scientific Corp has an average volume of 7.49M.
Based on the recent corporate insider activity of 159 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Cardiovascular, Rhythm Management, and MedSurg.
